DJIA 16,374.76 23.38 0.14%
NASDAQ 4,733.50 -16.48 -0.35%
S&P 500 1,951.13 2.27 0.12%
market minute promo

Regeneron Pharmaceuticals (NASDAQ: REGN)

508.51 -10.27 (-1.98%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

REGN $508.51 -1.98%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $523.45
Previous Close $518.78
Daily Range $506.83 - $523.64
52-Week Range $320.06 - $605.93
Market Cap $52.7B
P/E Ratio 131.01
Dividend (Yield) $0.00 (0.0%)
Volume 606,573
Average Daily Volume 814,378
Current FY EPS $10.65

Sector

Healthcare

Industry

Drug Makers

Regeneron Pharmaceuticals (REGN) Description

The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions. Website: http://www.regeneron.com/

News & Commentary

3 Stocks We're Watching In The Third Quarter

Here are three companies our analysts have their eyes on

The Zacks Analyst Blog Highlights: Google, Gilead Sciences, Regeneron Pharmaceuticals, Intuitive Sur

The Zacks Analyst Blog Highlights: Google, Gilead Sciences, Regeneron Pharmaceuticals, Intuitive Surgical and Amazon.com

3 Stocks Pushing The Drugs Industry Lower

Why Regeneron Pharmaceuticals (REGN) Could Be a Potential Winner

Regeneron and Sanofi Present Encouraging Praluent Data

Illumina Acquires GenoLogics, Boosts Genomic Sequencing

Amgen's Next-Generation Cholesterol Drug Is Approved, but Pricing Is a Huge Concern

Repatha gets the green light from the Food and Drug Administration, but pharmacy benefit managers and insurers are ready to give PCSK9 inhibitors the red light.

Intercept's (ICPT) OCA Under Priority Review in the U.S.

Amicus (FOLD) Signs Agreement to Acquire Scioderm

Applied Genetic Meets Enrolment Milestone in XLRS Study

See More REGN News...

REGN's Top Competitors

REGN $508.51 (-1.98%)
Current stock: REGN
AMGN $149.23 (-2.01%)
Current stock: AMGN
GILD $101.91 (-2.26%)
Current stock: GILD
BIIB $301.63 (-0.85%)
Current stock: BIIB